Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for Intermediate and High Risk Localized Prostate Adenocarcinoma (HYDRA)

NCT04945642 is registered in ClinicalTrials.gov with Jonsson Comprehensive Cancer Center as lead sponsor.

NCT NCT04945642
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04945642 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for Intermediate and High Risk Localized Prostate Adenocarcinoma (HYDRA)
Lead sponsor
Jonsson Comprehensive Cancer Center
Phase
Not applicable
Overall status
Recruiting
Start date
August 20, 2021
Completion date
July 1, 2028
Enrollment
52 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate adenocarcinoma, stage iib prostate cancer american joint committee on cancer (ajcc) v8, stage iic prostate cancer ajcc v8, stage iii prostate cancer ajcc v8, stage iiia prostate cancer ajcc v8, stage iiib prostate cancer ajcc v8, stage iiic prostate cancer ajcc v8, stage iva prostate cancer ajcc v8